BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19093176)

  • 1. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?
    Iacopetta B; Kawakami K; Watanabe T
    Int J Clin Oncol; 2008 Dec; 13(6):498-503. PubMed ID: 19093176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
    Van Rijnsoever M; Elsaleh H; Joseph D; McCaul K; Iacopetta B
    Clin Cancer Res; 2003 Aug; 9(8):2898-903. PubMed ID: 12912934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
    Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
    Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
    PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype.
    Kawakami K; Ooyama A; Ruszkiewicz A; Jin M; Watanabe G; Moore J; Oka T; Iacopetta B; Minamoto T
    Br J Cancer; 2008 May; 98(9):1555-61. PubMed ID: 18414409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.
    Juo YY; Johnston FM; Zhang DY; Juo HH; Wang H; Pappou EP; Yu T; Easwaran H; Baylin S; van Engeland M; Ahuja N
    Ann Oncol; 2014 Dec; 25(12):2314-2327. PubMed ID: 24718889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
    Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
    Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
    Ogino S; Nosho K; Kirkner GJ; Kawasaki T; Meyerhardt JA; Loda M; Giovannucci EL; Fuchs CS
    Gut; 2009 Jan; 58(1):90-6. PubMed ID: 18832519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma.
    An C; Choi IS; Yao JC; Worah S; Xie K; Mansfield PF; Ajani JA; Rashid A; Hamilton SR; Wu TT
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):656-63. PubMed ID: 15701853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer.
    Kawakami K; Matsunoki A; Kaneko M; Saito K; Watanabe G; Minamoto T
    Cancer Sci; 2011 Jan; 102(1):166-74. PubMed ID: 21087350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53.
    Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS; Ogino S
    Neoplasia; 2007 Dec; 9(12):1091-8. PubMed ID: 18084616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
    Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
    Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
    Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
    Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
    Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
    Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
    Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique DNA methylome profiles in CpG island methylator phenotype colon cancers.
    Xu Y; Hu B; Choi AJ; Gopalan B; Lee BH; Kalady MF; Church JM; Ting AH
    Genome Res; 2012 Feb; 22(2):283-91. PubMed ID: 21990380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
    Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
    Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer.
    Tanaka H; Deng G; Matsuzaki K; Kakar S; Kim GE; Miura S; Sleisenger MH; Kim YS
    Int J Cancer; 2006 Jun; 118(11):2765-71. PubMed ID: 16381005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.